Francesca Platini
University of Milan
CancerOncologyAdverse effectClinical endpointLenvatinibHead and neck cancerAxitinibChemotherapyHead and neck squamous-cell carcinomaEGFR inhibitorsCommon Terminology Criteria for Adverse EventsSalivary gland cancerAdenoid cystic carcinomaEpidermal growth factor receptorCetuximabAdenoidCancer researchRadiation therapyMedicineCohort
19Publications
4H-index
41Citations
Publications 22
Newest
PURPOSE To describe the management and outcomes of loco-regionally advanced (stages III-IV) laryngeal cancer (LRALC) in elderly patients. METHODS Clinical records of 88 LRALC patients treated at our Institution from 2002 to 2017 were retrospectively reviewed. Patients were divided in 2 subgroups: age > 65 years (elderly) and age ≤ 65 years (controls). Survivals were estimated with Kaplan-Meier method and compared with log-rank test, multivariate analysis were performed with Cox proportional haza...
Source
#1Cristiana BergaminiH-Index: 18
#2Stefano CavalieriH-Index: 8
Last. Lisa Licitra (University of Milan)H-Index: 54
view all 11 authors...
Source
#1Stefano CavalieriH-Index: 8
#2Luigi MarianiH-Index: 39
Last. Laura D. LocatiH-Index: 30
view all 17 authors...
Abstract Background Distant metastases in adenoid cystic carcinoma (ACC) are common. There is no consensus on the management of metastatic disease because no therapeutic approach has demonstrated improvement in overall survival (OS) and because of prolonged life expectancy. The aim of this study is to build and validate a prognostic nomogram for metastatic ACC patients. Methods The study end-point was OS, measured from the date of first metastatic presentation to death/last follow-up. A retrospe...
3 CitationsSource
#1Mauro GuglielmoH-Index: 2
#2Patricia Di PedeH-Index: 2
Last. Paolo Bossi (University of Milan)H-Index: 33
view all 11 authors...
PURPOSE Fatigue is a distressing symptom in head & neck cancer patients before during and at the end of curative therapy. Pharmacologic and not pharmacologic treatments have been proposed with scarce or no evidence of efficacy. The aim of the study is to evaluate the efficacy of American ginseng in respect to placebo in reducing fatigue in patients treated for head and neck cancer with curative intent. METHODS Thirty-two patients who had completed oncological treatment for a primary Head & neck ...
Source
#1Francesca PlatiniH-Index: 4
#2Elisa OrtolanH-Index: 1
Last. Laura D. LocatiH-Index: 30
view all 19 authors...
1 CitationsSource
#1Laura D. LocatiH-Index: 30
#2Donata GalbiatiH-Index: 5
Last. Lisa Licitra (University of Milan)H-Index: 54
view all 17 authors...
BACKGROUND: The treatment of patients with recurrent and/or metastatic (R/M) salivary gland adenoid cystic carcinoma (ACC) remains an unmet need. METHODS: Patients with R/M disease with a history of clinical or symptomatic disease progression within 6 months and a maximum of 1 previous line of chemotherapy or a multiple kinase inhibitor received oral lenvatinib at a dose of 24 mg/day. The primary endpoint was the objective response rate; secondary endpoints included quality of life (QOL) (accord...
6 CitationsSource
#1Salvatore AlfieriH-Index: 13
#2Andrea CarenzoH-Index: 3
Last. Loris De CeccoH-Index: 26
view all 20 authors...
Distant metastases (DM) in head and neck squamous cell carcinoma (HNSCC) remain a challenge as treatment options are limited. To identify biomarkers predictive of DM in primary tumors (PT), gene expression profiling was performed in PT from patients who did, or did not develop DM (T-with and T-without, n = 25 and 24, respectively), and in matched DM. A total of 185 and 42 differentially expressed genes were identified in the T-with vs. T-without and the T-with vs. DM comparisons, respectively. T...
3 CitationsSource
#1Donata GalbiatiH-Index: 5
#2Stefano CavalieriH-Index: 8
Last. Paolo BossiH-Index: 33
view all 11 authors...
Background: Unresectable or metastatic cutaneous squamous cell cancers (cSCCs) are rare but potentially life-threatening diseases. In this setting, systemic therapy has a palliative intent with limited benefit, but there is no established consensus regarding the proper management of this tumour. This retrospective study aimed to review outcomes in patients with non-curable cSCC treated with platinum-based chemotherapy and cetuximab. Methods: We considered 12 consecutive patients treated between ...
2 CitationsSource
BACKGROUND: Patients with prognosis recurrent/metastatic (R/M) salivary gland carcinomas (SGCs) are poor. Activity of axitinib was demonstrated in adenoid cystic carcinoma (ACC). We tested axitinib in a larger cohort of R/M SGCs including non-ACC. METHODS: Axitinib was administered at 10 mg daily (dose escalation allowed) until progression or unacceptable toxicity. Null hypothesis would be rejected if more than 3 of 26 responses were observed. RESULTS: Twenty-six patients (50% were male; 6 ACC, ...
4 CitationsSource
BACKGROUND: The aim of this study was to assess whether the early monitoring of the effects of bevacizumab in patients with recurrent glioblastoma multiforme (GBM) using perfusional dynamic susceptibility contrast (DSC) magnetic resonance imaging (MRI) before and after the beginning of antiangiogenic therapy is predictive of treatment response. METHODS: Thirteen patients with recurrent GBM underwent perfusion MRI with relative cerebral blood volume (rCBV) mapping before (T0) and after the beginn...
4 CitationsSource
123
Close Researchers